KR101076943B1 - 헷지호그 경로 조절제로서의 화합물 및 조성물 - Google Patents
헷지호그 경로 조절제로서의 화합물 및 조성물 Download PDFInfo
- Publication number
- KR101076943B1 KR101076943B1 KR1020087026986A KR20087026986A KR101076943B1 KR 101076943 B1 KR101076943 B1 KR 101076943B1 KR 1020087026986 A KR1020087026986 A KR 1020087026986A KR 20087026986 A KR20087026986 A KR 20087026986A KR 101076943 B1 KR101076943 B1 KR 101076943B1
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- biphenyl
- carboxylic acid
- amide
- pyridin
- Prior art date
Links
- 0 **c1*(*=O)c(O)cc(*)c1-c1c(*)c(I)c(*)c(*)c1* Chemical compound **c1*(*=O)c(O)cc(*)c1-c1c(*)c(I)c(*)c(*)c1* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/75—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Abstract
Description
Claims (12)
- 하기 화학식 I의 화합물, 그의 제약상 허용되는 염, 또는 입체이성질체.<화학식 I>상기 식에서,Y1 및 Y2는 N 및 CR10으로부터 독립적으로 선택되며, 여기서 R10은 수소이고;R1은 수소, 시아노, 할로, C1-6알킬, 할로치환된-C1-6알킬, C1-6알콕시, 할로치환된-C1-6알콕시, 디메틸-아미노, C1-6알킬-술파닐 및 피페라지닐 (2개 이하의 C1-6알킬 라디칼로 치환될 수 있음)로부터 선택되고;R2 및 R5는 수소, 시아노, 할로, C1-6알킬, 할로치환된-C1-6알킬, C1-6알콕시, 할로치환된-C1-6알콕시 및 디메틸아미노로부터 독립적으로 선택되고;R3 및 R4는 수소, 할로, 시아노, C1-6알킬, 할로치환된-C1-6알킬, C1-6알콕시 및 할로치환된-C1-6알콕시로부터 독립적으로 선택되고;R6 및 R7은 수소, 클로로, 플루오로, 브로모, C1-6알킬, 할로치환된-C1-6알킬, C1-6알콕시 및 할로치환된-C1-6알콕시로부터 독립적으로 선택되지만, 단, R6과 R7 둘 모두가 수소는 아니고;R8은 수소이고;R9는 -S(O)2R11, -OR11, -C(O)R11, -NR12aR12b 및 -R11로부터 선택되며, 여기서 R11이 티오모르폴리노, 술포노모르폴리노, 술파노모르폴리노, 모르폴리노, 시클로헥실, 페닐, 아제판-1-일, 2-옥소피페라진-1-일, 1,4-옥사제판-4-일, 피페리딘-1-일, 테트라히드로-2H-피란-4-일, 피페리딘-3-일, 피페라지닐, 피롤리디닐 및 1,4-디아제판-1-일로부터 선택되고, R12a 및 R12b가 이소부틸 및 히드록시-에틸로부터 독립적으로 선택되고;R9의 상기 티오모르폴리노, 술포노모르폴리노, 술파노모르폴리노, 모르폴리노, 시클로헥실, 페닐, 아제판-1-일, 2-옥소피페라진-1-일, 1,4-옥사제판-4-일, 피페리딘-1-일, 테트라히드로-2H-피란-4-일, 피페리딘-3-일, 피페라지닐, 피롤리디닐 또는 1,4-디아제판-1-일이 메틸, 에틸, 메톡시, 벤질, 티에닐-메틸, 피리디닐-메틸, 벤조[d][1,3]디옥솔-6-일 및 2,3-디히드로벤조[b][1,4]디옥신-7-일로부터 독립적으로 선택된 1 내지 3개의 라디칼로 치환될 수 있고,R9의 상기 페닐 또는 벤질 치환기가 메톡시, 에톡시, 메틸-피페라지닐, 메틸, 트리플루오로메톡시, 클로로, 플루오로 및 트리플루오로메틸로부터 독립적으로 선택된 1 내지 3개의 라디칼로 치환될 수 있다.
- 제1항에 있어서,Y1 및 Y2가 N 및 CR10으로부터 선택되며, 여기서 R10이 수소이고;R6 및 R7이 수소, 메틸, 클로로, 플루오로, 브로모, 트리플루오로메틸 및 메톡시로부터 독립적으로 선택되지만, 단, R6과 R7 둘 모두가 수소는 아니고;R8이 수소, 메틸 및 트리플루오로메틸로부터 선택되는 것인 화합물.
- 제2항에 있어서,R1이 시아노, 클로로, 플루오로, 메틸, 에틸, t-부틸, 프로필, 이소부틸, 이소프로필, 이소프로필옥시, 부톡시, 메톡시, 디메틸-아미노, 에톡시, 메틸-술파닐, 트리플루오로메틸, 트리플루오로메톡시 및 피페라지닐 (2개 이하의 메틸 라디칼로 임의로 치환됨)로부터 선택되고;R2 및 R5가 수소, 클로로, 플루오로, 시아노, 메틸, 트리플루오로메틸, 이소프로필옥시, 메톡시, 에톡시, 트리플루오로메톡시 및 디메틸아미노로부터 독립적으로 선택되고;R3 및 R4가 수소, 클로로, 메틸, 메톡시 및 시아노로부터 독립적으로 선택되는 것인 화합물.
- 제3항에 있어서,N-(6-((2R,6S)-2,6-디메틸모르폴리노)피리딘-3-일)-2-메틸-4'-(트리플루오로메톡시)비페닐-3-카르복스아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 [4-(모르폴린-4-술포닐)-페닐]-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 [6-(2,6-디메틸-모르폴린-4-일)-피리딘-3-일]-아미드,4'-시아노-2-메틸-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,4'-메톡시-2-메틸-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,4'-메톡시-2-메틸-비페닐-3-카르복실산 (4-시클로헥실-페닐)-아미드,4'-메톡시-2-메틸-비페닐-3-카르복실산 [6-(2-메틸-모르폴린-4-일)-피리딘-3-일]-아미드,4'-디메틸아미노-2-메틸-비페닐-3-카르복실산 (4-시클로헥실-페닐)-아미드,4'-디메틸아미노-2-메틸-비페닐-3-카르복실산 (4-모르폴린-4-일-페닐)-아미드,6-클로로-4'-디메틸아미노-비페닐-3-카르복실산 (6-[1,4]옥사제판-4-일-피리딘-3-일)-아미드,6-클로로-4'-디메틸아미노-비페닐-3-카르복실산 (6-모르폴린-4-일-피리딘-3-일)-아미드,6-클로로-4'-디메틸아미노-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,6-클로로-4'-메톡시-비페닐-3-카르복실산 [6-(2-메틸-모르폴린-4-일)-피리딘-3-일]-아미드,6-클로로-4'-메톡시-비페닐-3-카르복실산 (6-[1,4]옥사제판-4-일-피리딘-3-일)-아미드,6-클로로-4'-메톡시-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,6-클로로-4'-메톡시-비페닐-3-카르복실산 (6-모르폴린-4-일-피리딘-3-일)-아미드,4'-메톡시-6-메틸-비페닐-3-카르복실산 (6-모르폴린-4-일-피리딘-3-일)-아미드,4'-메톡시-6-메틸-비페닐-3-카르복실산 (6-[1,4]옥사제판-4-일-피리딘-3-일)-아미드,4'-메톡시-6-메틸-비페닐-3-카르복실산 [6-(2-메틸-모르폴린-4-일)-피리딘-3-일]-아미드,4'-디메틸아미노-6-메틸-비페닐-3-카르복실산 [6-(2-메틸-모르폴린-4-일)-피리딘-3-일]-아미드,4'-디메틸아미노-6-메틸-비페닐-3-카르복실산 (6-[1,4]옥사제판-4-일-피리딘-3-일)-아미드,4'-디메틸아미노-6-메틸-비페닐-3-카르복실산 (6-모르폴린-4-일-피리딘-3-일)-아미드,4'-메톡시-6-메틸-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,4'-에톡시-6-메틸-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,6-메틸-4'-메틸술파닐-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,4'-디메틸아미노-6-메틸-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,6-메틸-[1,1';4',1"]터페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,3'-클로로-6-메틸-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,2',4'-디클로로-6-메틸-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,2'-클로로-6-메틸-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,3'-클로로-6-메틸-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,3',4'-디클로로-6-메틸-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,3'-클로로-6-메틸-4'-트리플루오로메틸-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,6,4'-디메틸-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,4'-에틸-6-메틸-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,4'-tert-부틸-6-메틸-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,6-메틸-4'-프로필-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,4'-이소부틸-6-메틸-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,4'-이소프로필-6-메틸-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,6,2',6'-트리메틸-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,6,2',3'-트리메틸-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,6-메틸-4'-트리플루오로메틸-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,6-메틸-3'-트리플루오로메틸-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,6-메틸-3',5'-비스트리플루오로메틸-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,3'-이소프로폭시-6-메틸-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,3'-에톡시-6-메틸-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,2',6'-디메톡시-6-메틸-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,6-메틸-4'-트리플루오로메톡시-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,6-메틸-3'-트리플루오로메톡시-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,6-메틸-비페닐-3-카르복실산 (4-모르폴린-4-일-페닐)-아미드,4'-메톡시-6-메틸-비페닐-3-카르복실산 (4-모르폴린-4-일-페닐)-아미드,3'-메톡시-6-메틸-비페닐-3-카르복실산 (4-모르폴린-4-일-페닐)-아미드,3'-디메틸아미노-6-메틸-비페닐-3-카르복실산 (4-모르폴린-4-일-페닐)-아미드,4'-플루오로-6-메틸-비페닐-3-카르복실산 (4-모르폴린-4-일-페닐)-아미드,3'-플루오로-6-메틸-비페닐-3-카르복실산 (4-모르폴린-4-일-페닐)-아미드,2'-플루오로-6-메틸-비페닐-3-카르복실산 (4-모르폴린-4-일-페닐)-아미드,6-메틸-4'-(4-메틸-피페라진-1-일)-비페닐-3-카르복실산 (4-모르폴린-4-일-페닐)-아미드,2'-시아노-6-메틸-비페닐-3-카르복실산 (4-모르폴린-4-일-페닐)-아미드,3'-시아노-6-메틸-비페닐-3-카르복실산 (4-모르폴린-4-일-페닐)-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 (6-[1,4]옥사제판-4-일-피리딘-3-일)-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 [6-(2-메틸-모르폴린-4-일)-피리딘-3-일]-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 (3,4,5,6-테트라히드로-2H-[1,2']비피리디닐-5'-일)-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 (6-모르폴린-4-일-피리딘-3-일)-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 [6-(4-메틸-피페라진-1-일)-피리딘-3-일]-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 (4-모르폴린-4-일-페닐)-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 (4-시클로헥실-페닐)-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 비페닐-4-일아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 (4'-메톡시-비페닐-4-일)-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 [4-(4-벤질-피페라진-1-일)-페닐]-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 [4-(피페리딘-1-술포닐)-페닐]-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 [4-(피롤리딘-1-술포닐)-페닐]-아미드,4'-시아노-6-메톡시-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,4'-시아노-2-메톡시-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,4'-시아노-2-메틸-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,3'-플루오로-4'-메톡시-6-메틸-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,4'-이소프로폭시-6-메틸-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,4'-부톡시-6-메틸-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,3'-클로로-4'-메톡시-6-메틸-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,4'-메톡시-6,3'-디메틸-비페닐-3-카르복실산 (6-아제판-1-일-피리딘-3-일)-아미드,4'-시아노-2-메틸-비페닐-3-카르복실산 [4-(피페리딘-1-술포닐)-페닐]-아미드,4'-시아노-6-플루오로-비페닐-3-카르복실산 [4-(피페리딘-1-술포닐)-페닐]-아미드,6-브로모-4'-시아노-비페닐-3-카르복실산 [4-(피페리딘-1-술포닐)-페닐]-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 [6-(4-벤질-[1,4]디아제판-1-일)-피리딘-3-일]-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 [6-(4-티오펜-3-일메틸-[1,4]디아제판-1-일)-피리딘-3-일]-아미드,4'-시아노-2-메틸-비페닐-3-카르복실산 [6-(2,6-디메틸-모르폴린-4-일)-피리딘-3-일]-아미드,4'-메톡시-2-메틸-비페닐-3-카르복실산 [6-(2,6-디메틸-모르폴린-4-일)-피리딘-3-일]-아미드,2-메틸-4'-트리플루오로메틸-비페닐-3-카르복실산 [6-(2,6-디메틸-모르폴린-4-일)-피리딘-3-일]-아미드,2-메틸-4'-트리플루오로메톡시-비페닐-3-카르복실산 [6-(2,6-디메틸-모르폴린-4-일)-피리딘-3-일]-아미드,4'-시아노-2-메틸-비페닐-3-카르복실산 [6-(2-메틸-모르폴린-4-일)-피리딘-3-일]-아미드,4'-시아노-2-플루오로-비페닐-3-카르복실산 [4-(피페리딘-1-술포닐)-페닐]-아미드,4'-시아노-6-트리플루오로메틸-비페닐-3-카르복실산 [4-(피페리딘-1-술포닐)-페닐]-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 [6-(4-피리딘-4-일메틸-[1,4]디아제판-1-일)-피리딘-3-일]-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 [6-(4-피리딘-3-일메틸-[1,4]디아제판-1-일)-피리딘-3-일]-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 {6-[4-(2,6-디메톡시-벤질)-[1,4]디아제판-1-일]-피리딘-3-일}-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 {6-[4-(2-에톡시-벤질)-[1,4]디아제판-1-일]-피리딘-3-일}-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 (6-{4-[2-(4-메틸-피페라진-1-일)-벤질]-[1,4]디아제판-1-일}-피리딘-3-일)-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 {6-[4-(4-메톡시-2,3-디메틸-벤질)-[1,4]디아제판-1-일]-피리딘-3-일}-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 {6-[4-(2,3-디히드로-벤조[1,4]디옥신-6-일메틸)-[1,4]디아제판-1-일]-피리딘-3-일}-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 [6-(4-피리딘-2-일메틸-[1,4]디아제판-1-일)-피리딘-3-일]-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 [6-(4-벤조[1,3]디옥솔-4-일메틸-[1,4]디아제판-1-일)-피리딘-3-일]-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 {6-[4-(2-트리플루오로메톡시-벤질)-[1,4]디아제판-1-일]-피리딘-3-일}-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 {6-[4-(2-디메틸아미노-벤질)-[1,4]디아제판-1-일]-피리딘-3-일}-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 {6-[4-(2-클로로-5-트리플루오로메틸-벤질)-[1,4]디아제판-1-일]-피리딘-3-일}-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 {6-[4-(2,3-디플루오로-벤질)-[1,4]디아제판-1-일]-피리딘-3-일}-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 {6-[4-(2-클로로-4-플루오로-벤질)-[1,4]디아제판-1-일]-피리딘-3-일}-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 {6-[4-(2,6-디플루오로-벤질)-[1,4]디아제판-1-일]-피리딘-3-일}-아미드,2-클로로-4'-시아노-비페닐-3-카르복실산 [4-(피페리딘-1-술포닐)-페닐]-아미드,4'-시아노-6-트리플루오로메틸-비페닐-3-카르복실산 [6-(2,6-디메틸-모르폴린-4-일)-피리딘-3-일]-아미드,2-클로로-4'-시아노-비페닐-3-카르복실산 [6-(2,6-디메틸-모르폴린-4-일)-피리딘-3-일]-아미드,4'-시아노-6-에틸-비페닐-3-카르복실산 [6-(2,6-디메틸-모르폴린-4-일)-피리딘-3-일]-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 {6-[4-(3-플루오로-벤질)-피페라진-1-일]-피리딘-3-일}-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 {6-[4-(2-트리플루오로메톡시-벤질)-피페라진-1-일]-피리딘-3-일}-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 {6-[4-(3-클로로-벤질)-피페라진-1-일]-피리딘-3-일}-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 {6-[4-(4-이소부틸-벤질)-피페라진-1-일]-피리딘-3-일}-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 {6-[4-(4-tert-부틸-벤질)-피페라진-1-일]-피리딘-3-일}-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 {6-[4-(7-메톡시-벤조[1,3]디옥솔-5-일메틸)-피페라진-1-일]-피리딘-3-일}-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 [6-(4-벤질-피페라진-1-일)-피리딘-3-일]-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 [6-(4-피리딘-3-일메틸-피페라진-1-일)-피리딘-3-일]-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 {6-[4-(4-디플루오로메톡시-벤질)-피페라진-1-일]-피리딘-3-일}-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 {6-[4-(4-시아노-벤질)-피페라진-1-일]-피리딘-3-일}-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 [6-(4-퀴놀린-5-일메틸-피페라진-1-일)-피리딘-3-일]-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 [6-(4-피리딘-4-일메틸-피페라진-1-일)-피리딘-3-일]-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 [6-(4-피리딘-2-일메틸-피페라진-1-일)-피리딘-3-일]-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 {6-[4-(4-이미다졸-1-일-벤질)-피페라진-1-일]-피리딘-3-일}-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 {6-[4-(3-시아노-벤질)-피페라진-1-일]-피리딘-3-일}-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 [6-(4-이소퀴놀린-5-일메틸-피페라진-1-일)-피리딘-3-일]-아미드,(R)-2-메틸-N-(6-(2-메틸모르폴리노)피리딘-3-일)-4'-(트리플루오로메톡시)비페닐-3-카르복스아미드,4'-시아노-2-메틸-N-(6-술포닐모르폴리노피리딘-3-일)비페닐-3-카르복스아미드,(S)-4'-시아노-2-메틸-N-(6-(2-메틸모르폴리노)피리딘-3-일)비페닐-3-카르복스아미드,(R)-6-클로로-N-(6-(2-메틸모르폴리노)피리딘-3-일)-4'-(트리플루오로메톡시)비페닐-3-카르복스아미드,4'-시아노-2-메틸-N-(6-술피닐모르폴리노피리딘-3-일)비페닐-3-카르복스아미드,4'-시아노-N-(6-(디이소부틸아미노)피리딘-3-일)-2-메틸비페닐-3-카르복스아미드,4'-시아노-N-(2-((2S,6R)-2,6-디메틸모르폴리노)피리미딘-5-일)-2-메틸비페닐-3-카르복스아미드,N-(2-((2S,6R)-2,6-디메틸모르폴리노)피리미딘-5-일)-2-메틸-4'-(트리플루오로메틸)비페닐-3-카르복스아미드,N-(2-((2S,6R)-2,6-디메틸모르폴리노)피리미딘-5-일)-2-메틸-4'-(트리플루오로메톡시)비페닐-3-카르복스아미드,N-(2-(비스(2-히드록시에틸)아미노)피리미딘-5-일)-2-메틸-4'-(트리플루오로메톡시)비페닐-3-카르복스아미드,2-메틸-N-(6-(테트라히드로-2H-피란-4-일옥시)피리딘-3-일)-4'-(트리플루오로메톡시)비페닐-3-카르복스아미드,N-(6-((2R,6S)-2,6-디메틸테트라히드로-2H-피란-4-일)피리딘-3-일)-2-메틸-4'-(트리플루오로메톡시)비페닐-3-카르복스아미드,N-(6-(4-에틸피페라진-1-카르보닐)피리딘-3-일)-2-메틸-4'-(트리플루오로메톡시)비페닐-3-카르복스아미드,2-메틸-N-(6-(2-옥소피페라진-1-일)피리딘-3-일)-4'-(트리플루오로메톡시)비페닐-3-카르복스아미드,2-메틸-N-(6-(1-(피리딘-4-일메틸)피페리딘-4-일)피리딘-3-일)-4'-(트리플루오로메톡시)비페닐-3-카르복스아미드,2-메틸-N-(6-(2-옥소-4-(피리딘-4-일메틸)피페라진-1-일)피리딘-3-일)-4'-(트리플루오로메톡시)비페닐-3-카르복스아미드,2-메틸-N-(6-(1-(피리딘-4-일메틸)피페리딘-3-일)피리딘-3-일)-4'-(트리플루오로메톡시)비페닐-3-카르복스아미드 및N-(6-(1-에틸피페리딘-3-일)피리딘-3-일)-2-메틸-4'-(트리플루오로메톡시)비페닐-3-카르복스아미드로부터 선택된 화합물, 그의 제약상 허용되는 염, 또는 입체이성질체.
- N-(6-((2R,6S)-2,6-디메틸모르폴리노)피리딘-3-일)-2-메틸-4'-(트리플루오로메톡시)비페닐-3-카르복스아미드, 그의 제약상 허용되는 염, 또는 입체이성질체.
- 4'-(2-디메틸아미노-에톡시)-6-메틸-비페닐-3-카르복실산 (4-모르폴린-4-일-페닐)-아미드,4-메틸-N-(4-모르폴린-4-일-페닐)-3-퀴녹살린-6-일-벤즈아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 (3-플루오로-4-모르폴린-4-일-페닐)-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 (3-클로로-4-모르폴린-4-일-페닐)-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 (3-브로모-4-모르폴린-4-일-페닐)-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 (3-메틸-4-모르폴린-4-일-페닐)-아미드,4'-시아노-6-메틸-비페닐-3-카르복실산 (4-모르폴린-4-일-3-트리플루오로메틸-페닐)-아미드, 및N-(5-클로로-6-((2S,6R)-2,6-디메틸모르폴리노)피리딘-3-일)-2-메틸-4'-(트리플루오로메톡시)비페닐-3-카르복스아미드로부터 선택되는 화합물, 또는 그의 제약상 허용되는 염.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79794906P | 2006-05-05 | 2006-05-05 | |
US60/797,949 | 2006-05-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20080108343A KR20080108343A (ko) | 2008-12-12 |
KR101076943B1 true KR101076943B1 (ko) | 2011-10-26 |
Family
ID=38668605
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020087026986A KR101076943B1 (ko) | 2006-05-05 | 2007-05-04 | 헷지호그 경로 조절제로서의 화합물 및 조성물 |
Country Status (46)
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA93548C2 (uk) * | 2006-05-05 | 2011-02-25 | Айерем Елелсі | Сполуки та композиції як модулятори хеджхогівського сигнального шляху |
TWI433674B (zh) | 2006-12-28 | 2014-04-11 | Infinity Discovery Inc | 環杷明(cyclopamine)類似物類 |
BR122021010386B1 (pt) * | 2007-06-07 | 2021-08-03 | Sun Pharma Global Fze | Uso de n-(6-((2r,6s)-2,6-dimetilmorfolino)piridin-3-il)-2-metil-4'-(trifluorometoxi) bifenil-3- carboxamida como moduladores da rota de hedgehog |
AU2014280951B2 (en) * | 2007-06-07 | 2016-10-13 | Sun Pharmaceutical Industries Limited | Biphenylcarboxamide derivatives as hedgehog pathway modulators |
AU2008326381B2 (en) * | 2007-11-21 | 2014-10-23 | Decode Genetics Ehf | Biaryl PDE4 inhibitors for treating inflammation |
AU2008345097A1 (en) | 2007-12-27 | 2009-07-09 | Infinity Pharmaceuticals, Inc. | Methods for stereoselective reduction |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
US20090281089A1 (en) * | 2008-04-11 | 2009-11-12 | Genentech, Inc. | Pyridyl inhibitors of hedgehog signalling |
US8063043B2 (en) | 2008-09-17 | 2011-11-22 | Novartis Ag | Salts of N-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4′-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide |
EP2617414A3 (en) * | 2008-10-01 | 2013-11-06 | Novartis AG | Smoothened antagonism for the treatment of hedgehog pathway-related disorders |
WO2010052448A2 (en) * | 2008-11-05 | 2010-05-14 | Ucb Pharma S.A. | Fused pyrazine derivatives as kinase inhibitors |
AR077490A1 (es) * | 2009-07-21 | 2011-08-31 | Novartis Ag | Composiciones farmaceuticas topicas para el tratamiento de una condicion hiperproliferativa de la piel |
CA2769795C (en) | 2009-08-05 | 2020-01-07 | Infinity Pharmaceuticals, Inc. | Enzymatic transamination of cyclopamine analogs |
US20110039850A1 (en) * | 2009-08-12 | 2011-02-17 | Mhairi Copland | Leukemia Treatment |
KR20120107962A (ko) | 2009-11-18 | 2012-10-04 | 노파르티스 아게 | 고형 종양 및 다른 악성종양의 치료를 위한 방법 및 조성물 |
ES2593256T3 (es) | 2010-05-21 | 2016-12-07 | Infinity Pharmaceuticals, Inc. | Compuestos químicos, composiciones y métodos para las modulaciones de cinasas |
WO2012037217A1 (en) | 2010-09-14 | 2012-03-22 | Infinity Pharmaceuticals, Inc. | Transfer hydrogenation of cyclopamine analogs |
CN101993415B (zh) * | 2010-09-15 | 2013-08-14 | 北京韩美药品有限公司 | 作为Hedgehog通路抑制剂的化合物以及包含该化合物的药物组合物及其应用 |
WO2012064973A2 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CN103648499B (zh) | 2011-01-10 | 2017-02-15 | 无限药品股份有限公司 | 用于制备异喹啉酮的方法及异喹啉酮的固体形式 |
WO2012166241A1 (en) | 2011-06-02 | 2012-12-06 | Novartis Ag | Biomarkers for hedgehog inhibitor therapy |
EP2734520B1 (en) | 2011-07-19 | 2016-09-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CA2842190A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
WO2013032591A1 (en) | 2011-08-29 | 2013-03-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
US9630979B2 (en) | 2011-09-29 | 2017-04-25 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9512106B2 (en) | 2012-09-17 | 2016-12-06 | Duke University | Smoothened modulators and methods of use thereof |
TWI588131B (zh) * | 2012-10-15 | 2017-06-21 | 雅酶股份有限公司 | 經取代苯化合物 |
ES2691742T5 (es) | 2012-11-01 | 2022-03-18 | Infinity Pharmaceuticals Inc | Tratamiento de cánceres utilizando moduladores de isoformas de PI3 cinasa |
AU2013352256A1 (en) | 2012-11-29 | 2015-06-18 | Strasspharma, Llc | Methods of modulating follicle stimulating hormone activity |
CN103910736B (zh) * | 2013-01-08 | 2017-11-17 | 江苏先声药业有限公司 | 一类二氢吡喃并嘧啶衍生物及其医药应用 |
NZ629037A (en) | 2013-03-15 | 2017-04-28 | Infinity Pharmaceuticals Inc | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
US9192609B2 (en) | 2013-04-17 | 2015-11-24 | Hedgepath Pharmaceuticals, Inc. | Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors |
US20160113932A1 (en) | 2013-05-30 | 2016-04-28 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CA2925944C (en) | 2013-10-04 | 2023-01-10 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2015061204A1 (en) | 2013-10-21 | 2015-04-30 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2015092720A1 (en) * | 2013-12-19 | 2015-06-25 | Novartis Ag | Metabolites of sonidegib (lde225) |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
ME03558B (me) | 2014-03-14 | 2020-07-20 | Novartis Ag | Molekuli anti-lag-3 antiтela i njihove upotrebe |
EP4066834A1 (en) | 2014-03-19 | 2022-10-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
SG11201607973XA (en) | 2014-03-24 | 2016-11-29 | Guangdong Zhongsheng Pharmaceutical Co Ltd | Quinoline derivatives as smo inhibitors |
US20150320754A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
WO2015168079A1 (en) | 2014-04-29 | 2015-11-05 | Infinity Pharmaceuticals, Inc. | Pyrimidine or pyridine derivatives useful as pi3k inhibitors |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
CU20170052A7 (es) | 2014-10-14 | 2017-11-07 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo que se unen a pd-l1 |
WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
KR20170129802A (ko) | 2015-03-10 | 2017-11-27 | 아두로 바이오테크, 인코포레이티드 | "인터페론 유전자의 자극인자"-의존적 신호전달을 활성화하는 조성물 및 방법 |
US10266523B2 (en) * | 2015-03-30 | 2019-04-23 | Crystal Pharmatech Co., Ltd. | Crystaline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-Methyl-4′-(trifluoromethoxy) [1,1′-biphenyl]-3-Methanamide monophosphate, and process of preparation thereof |
MX2017015681A (es) | 2015-06-04 | 2018-09-11 | Pellepharm Inc | Formulaciones topicas para suministrar compuestos inhibidores de hedgehog y uso de los mismos. |
CA2987067A1 (en) * | 2015-06-05 | 2016-12-08 | Dana-Farber Cancer Institute, Inc. | Compounds and methods for treating cancer |
SI3317301T1 (sl) | 2015-07-29 | 2021-10-29 | Novartis Ag | Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3 |
WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
BR112018008891A8 (pt) | 2015-11-03 | 2019-02-26 | Janssen Biotech Inc | anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos |
WO2017083216A1 (en) * | 2015-11-12 | 2017-05-18 | Merck Sharp & Dohme Corp. | Cyanopyridine derivatives as liver x receptor beta agonists, compositions, and their use |
JP2019503349A (ja) | 2015-12-17 | 2019-02-07 | ノバルティス アーゲー | Pd−1に対する抗体分子およびその使用 |
WO2017139497A1 (en) | 2016-02-11 | 2017-08-17 | PellePharm, Inc. | Hedgehog inhibitor for use in relief of and treatment of pruritus or itching |
WO2017163258A1 (en) * | 2016-03-22 | 2017-09-28 | Msn Laboratories Private Limited | Process for the preparation of n-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2- methyl-4'-(trifiuoromethoxy) [1,1' -biphenyi]-3-carboxamide and its polymorphs thereof |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2017223422A1 (en) | 2016-06-24 | 2017-12-28 | Infinity Pharmaceuticals, Inc. | Combination therapies |
WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
JOP20190106A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
EP4173639A4 (en) | 2020-06-26 | 2024-03-13 | Raqualia Pharma Inc | METHOD FOR SELECTING A CANCER PATIENT WITH EFFECT OF COMBINATION THERAPY WITH RETINOID AND CANCER TREATMENT |
KR20230153959A (ko) * | 2022-04-29 | 2023-11-07 | 제일약품주식회사 | 신규한 pim 키나아제 억제 화합물 및 이의 용도 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005030206A1 (en) * | 2003-09-24 | 2005-04-07 | Imclone Systems Incorporated | Aryl-1,3-azole derivatives and methods for inhibiting heparnase activity |
WO2006028958A2 (en) * | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Pyridyl inhibitors of hedgehog signalling |
WO2006044975A2 (en) * | 2004-10-19 | 2006-04-27 | Compass Pharmaceuticals Llc | Compositions and their use as anti-tumor agents |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2741881B1 (fr) | 1995-12-01 | 1999-07-30 | Centre Nat Rech Scient | Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques |
AU9781098A (en) | 1997-10-02 | 1999-04-27 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
US6335459B1 (en) | 1998-12-23 | 2002-01-01 | Syntex (U.S.A.) Llc | Aryl carboxylic acid and aryl tetrazole derivatives as IP receptor modulators |
US20020052343A1 (en) | 1999-12-15 | 2002-05-02 | Allen Darin Arthur | Salicylamides as serine protease inhibitors |
CA2394646A1 (en) | 1999-12-17 | 2001-06-21 | Ariad Pharmaceuticals, Inc. | Novel purines |
US20030187261A1 (en) | 2000-01-07 | 2003-10-02 | Libor Havlicek | Purine derivatives, process for their preparation and use thereof |
WO2002000216A1 (en) * | 2000-06-28 | 2002-01-03 | Teva Pharmaceutical Industries Ltd. | Carvedilol |
GB0022438D0 (en) | 2000-09-13 | 2000-11-01 | Novartis Ag | Organic Compounds |
JP2002338537A (ja) | 2001-05-16 | 2002-11-27 | Mitsubishi Pharma Corp | アミド化合物およびその医薬用途 |
SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
JP2005538975A (ja) | 2002-07-03 | 2005-12-22 | アステックス テクノロジー リミテッド | p38MAPキナーゼ阻害薬としての3−(ヘテロ)アリールメトキシピリジン類およびそれらの類縁体 |
US20030139427A1 (en) * | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
US7642277B2 (en) | 2002-12-04 | 2010-01-05 | Boehringer Ingelheim International Gmbh | Non-nucleoside reverse transcriptase inhibitors |
DE10306250A1 (de) | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
CA2531796A1 (en) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
US20070161582A1 (en) * | 2003-08-08 | 2007-07-12 | Dusan Mijikovic | Pharmaceutical compositions and methods for metabolic modulation |
US7504401B2 (en) * | 2003-08-29 | 2009-03-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
AU2004270733B2 (en) | 2003-09-11 | 2011-05-19 | Itherx Pharma, Inc. | Cytokine inhibitors |
WO2005033288A2 (en) * | 2003-09-29 | 2005-04-14 | The Johns Hopkins University | Hedgehog pathway antagonists |
AR046698A1 (es) | 2003-11-11 | 2005-12-21 | Ishihara Sangyo Kaisha | Derivado bifenilo o su sal, y pesticida que lo contienen como un ingrediente activo |
AU2004308974A1 (en) | 2003-12-22 | 2005-07-14 | Gilead Sciences, Inc. | Kinase inhibitor phosphonate conjugates |
EP1745041B1 (en) * | 2004-04-30 | 2012-06-20 | Genentech, Inc. | Quinoxaline inhibitors of the hedgehog signalling pathway |
US7683097B2 (en) * | 2004-05-27 | 2010-03-23 | Propharmacon Inc. | Topoisomerase inhibitors |
GB0420719D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
US20070054916A1 (en) * | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
FR2876583B1 (fr) | 2004-10-15 | 2007-04-13 | Centre Nat Rech Scient Cnrse | Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules |
GT200500321A (es) | 2004-11-09 | 2006-09-04 | Compuestos y composiciones como inhibidores de proteina kinase. | |
EP1844003A4 (en) | 2005-01-27 | 2010-09-22 | Astrazeneca Ab | NEW BIAROMATIC COMPOUNDS AS INHIBITORS OF THE P2X7 RECEPTOR |
WO2006118914A2 (en) * | 2005-04-29 | 2006-11-09 | Children's Medical Center Corporation | Methods of increasing proliferation of adult mammalian cardiomyocytes through p38 map kinase inhibition |
US8138198B2 (en) | 2005-05-18 | 2012-03-20 | Angibaud Patrick Rene | Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase |
EP1904047B1 (en) | 2005-07-07 | 2013-01-02 | Abbott Laboratories | Apoptosis promoters |
US8008303B2 (en) * | 2005-09-16 | 2011-08-30 | Astrazeneca Ab | Biphenyl derivatives and their use in treating hepatitis C |
UA93548C2 (uk) * | 2006-05-05 | 2011-02-25 | Айерем Елелсі | Сполуки та композиції як модулятори хеджхогівського сигнального шляху |
US20080280891A1 (en) * | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
PE20080948A1 (es) | 2006-07-25 | 2008-09-10 | Irm Llc | Derivados de imidazol como moduladores de la senda de hedgehog |
EP2617423A1 (en) | 2006-10-19 | 2013-07-24 | Genzyme Corporation | Purine derivatives for the treatment of cystic diseases |
DE102006062203A1 (de) | 2006-12-22 | 2008-06-26 | Curacyte Discovery Gmbh | Substituierte 5H-Pyrimido[5,4-b]indole als Induktoren der Apoptose bei B-CLL Zellen |
BR122021010386B1 (pt) | 2007-06-07 | 2021-08-03 | Sun Pharma Global Fze | Uso de n-(6-((2r,6s)-2,6-dimetilmorfolino)piridin-3-il)-2-metil-4'-(trifluorometoxi) bifenil-3- carboxamida como moduladores da rota de hedgehog |
WO2009009041A2 (en) | 2007-07-06 | 2009-01-15 | Kinex Pharmaceuticals, Llc | Compositions and methods for modulating a kinase cascade |
CA2707492A1 (en) | 2007-12-13 | 2009-06-18 | Amgen Inc. | Gamma secretase modulators |
WO2009078992A1 (en) | 2007-12-17 | 2009-06-25 | Amgen Inc. | Linear tricyclic compounds as p38 kinase inhibitors |
-
2007
- 2007-04-05 UA UAA200812916A patent/UA93548C2/uk unknown
- 2007-05-02 JO JO2007172A patent/JO2883B1/en active
- 2007-05-04 SI SI200731266T patent/SI2021328T1/sl unknown
- 2007-05-04 CN CN201210244325.5A patent/CN102746285B/zh active Active
- 2007-05-04 AU AU2007247860A patent/AU2007247860C1/en active Active
- 2007-05-04 CL CL200701269A patent/CL2007001269A1/es unknown
- 2007-05-04 PL PL11165059T patent/PL2363393T3/pl unknown
- 2007-05-04 RU RU2008147663/04A patent/RU2413718C2/ru active IP Right Revival
- 2007-05-04 TW TW096115794A patent/TWI369352B/zh active
- 2007-05-04 GE GEAP200710965A patent/GEP20105103B/en unknown
- 2007-05-04 EP EP07761921A patent/EP2021328B1/en active Active
- 2007-05-04 MX MX2008014190A patent/MX2008014190A/es active IP Right Grant
- 2007-05-04 NZ NZ572362A patent/NZ572362A/en unknown
- 2007-05-04 SG SG2011041126A patent/SG172680A1/en unknown
- 2007-05-04 MY MYPI20084275A patent/MY153574A/en unknown
- 2007-05-04 CN CNA200780016150XA patent/CN101437800A/zh active Pending
- 2007-05-04 DK DK07761921.1T patent/DK2021328T3/da active
- 2007-05-04 WO PCT/US2007/068292 patent/WO2007131201A2/en active Search and Examination
- 2007-05-04 EP EP11165059.4A patent/EP2363393B1/en active Active
- 2007-05-04 PT PT111650594T patent/PT2363393E/pt unknown
- 2007-05-04 JP JP2009510112A patent/JP4891396B2/ja active Active
- 2007-05-04 AR ARP070101945A patent/AR060858A1/es active IP Right Grant
- 2007-05-04 PT PT77619211T patent/PT2021328E/pt unknown
- 2007-05-04 KR KR1020087026986A patent/KR101076943B1/ko active IP Right Grant
- 2007-05-04 PL PL07761921T patent/PL2021328T3/pl unknown
- 2007-05-04 CA CA2650248A patent/CA2650248C/en active Active
- 2007-05-04 ME MEP-2008-556A patent/ME00417B/me unknown
- 2007-05-04 EA EA200870504A patent/EA018302B1/ru not_active IP Right Cessation
- 2007-05-04 SM SM200800056T patent/SMP200800056B/it unknown
- 2007-05-04 US US12/299,290 patent/US8178563B2/en active Active
- 2007-05-04 ES ES07761921T patent/ES2422557T3/es active Active
- 2007-05-04 PE PE2007000547A patent/PE20080418A1/es active IP Right Grant
- 2007-05-04 BR BRPI0711333A patent/BRPI0711333B8/pt active IP Right Grant
- 2007-05-04 ES ES11165059.4T patent/ES2552347T3/es active Active
-
2008
- 2008-10-20 ZA ZA200808962A patent/ZA200808962B/xx unknown
- 2008-10-22 IL IL194818A patent/IL194818A/en active Protection Beyond IP Right Term
- 2008-10-24 CR CR10399A patent/CR10399A/es unknown
- 2008-10-31 TN TNP2008000437A patent/TNSN08437A1/en unknown
- 2008-11-03 GT GT200800237A patent/GT200800237A/es unknown
- 2008-11-05 SV SV2008003089A patent/SV2008003089A/es active IP Right Grant
- 2008-11-05 EC EC2008008860A patent/ECSP088860A/es unknown
- 2008-11-05 HN HN2008001652A patent/HN2008001652A/es unknown
- 2008-11-05 CU CU20080202A patent/CU23760B7/es active IP Right Grant
- 2008-11-24 MA MA31405A patent/MA30426B1/fr unknown
- 2008-12-03 NO NO20085059A patent/NO341215B1/no unknown
-
2009
- 2009-07-13 HK HK09106269.2A patent/HK1127043A1/xx unknown
-
2011
- 2011-08-31 JP JP2011189963A patent/JP5603308B2/ja active Active
-
2012
- 2012-04-10 US US13/443,631 patent/US20120196849A1/en not_active Abandoned
-
2015
- 2015-11-20 LU LU92883C patent/LU92883I2/xx unknown
- 2015-12-11 HU HUS1500065C patent/HUS1500065I1/hu unknown
- 2015-12-14 CY CY2015054C patent/CY2015054I1/el unknown
- 2015-12-15 LT LTPA2015051C patent/LTC2021328I2/lt unknown
-
2016
- 2016-01-13 NL NL300790C patent/NL300790I1/nl unknown
-
2017
- 2017-08-25 AR ARP170102364A patent/AR109423A2/es active IP Right Grant
- 2017-08-29 NO NO20171395A patent/NO341889B1/no active Protection Beyond IP Right Term
-
2018
- 2018-06-28 NO NO2018021C patent/NO2018021I1/no unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005030206A1 (en) * | 2003-09-24 | 2005-04-07 | Imclone Systems Incorporated | Aryl-1,3-azole derivatives and methods for inhibiting heparnase activity |
WO2006028958A2 (en) * | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Pyridyl inhibitors of hedgehog signalling |
WO2006044975A2 (en) * | 2004-10-19 | 2006-04-27 | Compass Pharmaceuticals Llc | Compositions and their use as anti-tumor agents |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101076943B1 (ko) | 헷지호그 경로 조절제로서의 화합물 및 조성물 | |
KR101217316B1 (ko) | 헷지호그 경로 조절제로서의 바이페닐카르복스아미드 유도체 | |
WO2006050351A2 (en) | Compounds and compositions as hedgehog pathway modulators | |
AU2014280951B2 (en) | Biphenylcarboxamide derivatives as hedgehog pathway modulators | |
AU2012202646A1 (en) | Biphenylcarboxamide derivatives as hedgehog pathway modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20140923 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20150918 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20160921 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20171012 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20181011 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20191008 Year of fee payment: 9 |